WeightWatchers aims to streamline the patient experience with convenient access to medication approved by the Food and Drug Administration as well as lifestyle support, Novo Nordisk said ...

Novo Nordisk has launched Wegovy in India, a weight-loss drug challenging Eli Lilly's Mounjaro. Available by June 2025, Wegovy is a once-weekly inject ...

PERTH, Western Australia, June 24, 2025 (GLOBE NEWSWIRE) -- Novo Resources Corp. (Novo or the Company) (ASX: NVO) (TSX: NVO) (OTCQX: NSRPF) reports that all resolutions proposed to shareholders at ...

Hims & Hers Stock Drops More Than 30% After Novo Nordisk Breakup. Wegovy maker cuts ties with telehealth company, citing allegations of deceptive marketing practices and drug compounding. By .

Hims & Hers stock plunged 30% on Monday after Novo Nordisk abruptly ended a collaboration to offer direct access to its weight loss drug Wegovy.

Drugmaker Novo Nordisk said on Monday it would halt its Wegovy weight-loss drug agreement with U.S. telehealth company Hims & Hers Health, pushing Hims shares down 31% in morning trading.

Novo Nordisk is ending a partnership with Hims & Hers. The fallout comes over claims the telehealth platform sold copycat versions of the pharmaceutical giant’s weight-loss drug Wegovy.. The ...

Novo Nordisk (NVO) closed at $69.72 in the latest trading session, marking a -5.49% move from the prior day. The stock's performance was behind the S&P 500's daily gain of 0.96%. Elsewhere, the ...

GSK, Gilead, Novo Nordisk join other Big Pharmas in honoring 2025 LGBTQ+ Pride Month. By Andrea Park Jun 26, 2025 3:31pm. LGBTQ+ Diversity Novo Nordisk Novartis. Many major ...

Shares in Denmark's pharmaceutical giant Novo Nordisk (NVO 0.63%) were lower by 4% as of 11 a.m. ET today. The move comes as the fallout from the sudden termination of its partnership with ...

Hims & Hers stock plummeted nearly 35% Monday after Novo Nordisk announced it was ending a collaboration to make its blockbuster weight-loss drug, Wegovy, available on Hims' telehealth platform.

Novo Nordisk shares tumble 5.6% after ending Hims & Hers partnership and releasing disappointing CagriSema obesity drug trial results on Monday trading.